Pharmacogenetics guided anticoagulation : Clinical Chemistry and Laboratory Medicine Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

Pharmacogenetics guided anticoagulation

Raute Sunder-Plassmann1 / 1

1Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Corresponding author: Christine Mannhalter, Department of Laboratory Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Austria Phone: +43 1404002085, Fax: +43 1404002097

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Pages S119–S127, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2010.370, November 2010

Publication History

Received:
2010-07-30
Accepted:
2010-10-05
Published Online:
2010-11-10

Abstract

Advances in the field of human genetics has made it possible to develop prevention strategies for rare genetic disorders and to tailor pharmacotherapeutic approaches to anticoagulation and certain cancers. However, it is still not clear how genetic variations influence the risk and outcome of common diseases. Data from genome-wide association studies is just beginning to answer these questions. In contrast, pharmacogenetic knowledge is frequently not yet translated into clinical practice, even though in some cases, particularly regarding drugs used in treatment of thrombotic diseases (e.g., coumarines, platelet aggregation inhibitors), it is already known that testing for genetic variants prior to pharmacotherapy may help to prevent severe adverse drug reactions or avoid therapeutic failure. In this review, we address the potential impact that genetic alterations in the genes for vitamin K epoxide reductase and some cytochrome P450 variants may have on therapeutic strategies in anticoagulation.

Clin Chem Lab Med 2010;48:S119–27.

Keywords: anticoagulation; CYP2C9; CYP2C19; pharmacogenetics; vitamin K epoxide reductase

Comments (0)

Please log in or register to comment.